Empresa BioCryst Pharmaceuticals, Inc.
Acciones
BCRX
US09058V1035
Biotecnología e investigación médica
Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
4,16 USD | 0,00 % | -6,09 % | -30,55 % |
Resumen de negocios
Número de empleados: 536
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Oral Small Molecule and Protein Therapeutics
100,0
%
| 271 | 100,0 % | 331 | 100,0 % | +22,37 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
87,0
%
| - | - | 288 | 87,0 % | - |
Non-United States
11,4
%
| - | - | 38 | 11,4 % | - |
Global
1,6
%
| 271 | 100,0 % | 5 | 1,6 % | -98,00 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 01/01/07 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 02/04/20 |
Ryan Arnold
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/22 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 20/09/19 |
Philip George
PRN | Corporate Officer/Principal | - | 01/09/22 |
Corporate Officer/Principal | - | 01/01/15 | |
Charles Gayer
PRN | Corporate Officer/Principal | 53 | 01/08/15 |
Human Resources Officer | - | 01/11/18 | |
Salisa Hauptmann
LAW | General Counsel | - | 01/01/21 |
Corporate Officer/Principal | 61 | 01/01/23 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 27/02/20 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 01/01/07 |
Director/Board Member | 60 | 26/07/21 | |
Stephen Aselage
BRD | Director/Board Member | 73 | 04/01/19 |
Director/Board Member | 69 | 10/10/11 | |
Nancy Hutson
CHM | Chairman | 74 | 20/01/12 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 20/09/19 |
Steven Galson
BRD | Director/Board Member | 67 | 01/09/21 |
Theresa Heggie
BRD | Director/Board Member | 63 | 03/12/18 |
Amy McKee
BRD | Director/Board Member | 52 | 20/09/21 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 206 330 603 | 199 798 093 ( 96,83 %) | 0 | 96,83 % |
Información de la empresa
BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard Suite 200
27703-8457, Durham
+919 859 1302
http://www.biocryst.comSector
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
-30,55 % | 858 M | |
-2,31 % | 103 mil M | |
+0,56 % | 95,28 mil M | |
+1,69 % | 22,15 mil M | |
-17,37 % | 21,02 mil M | |
-9,30 % | 18,15 mil M | |
-41,01 % | 16,74 mil M | |
-14,85 % | 16,05 mil M | |
+3,21 % | 13,68 mil M | |
+33,54 % | 12,17 mil M |
- Bolsa de valores
- Acciones
- Acción BCRX
- Empresa BioCryst Pharmaceuticals, Inc.